United Therapeutics Corp (UTHR) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lu...
United Therapeutics Corp's revenue increased 10.6% year over year, from $2.88B to $3.18B.
Net income increased 11.7% over the same period, from $1.20B to $1.33B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 99% in total.
Operating cash flow grew 17.6% to $1.56B.
United Therapeutics Corp maintains a strong net profit margin of 41.9%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $714.9M+5.5% | $278.1M | $637.1M | $319.9M | $232.2M | $6.72B | $100.0M | $5.70B |
| Q3 FY2024 | $748.9M+4.8% | $309.1M | $665.8M | $343.1M | $377.2M | $7.12B | $0 | $6.10B |
| Q4 FY2024 | $735.9M-1.7% | $301.3M | $660.0M | $357.7M | $341.2M | $7.36B | $0 | $6.44B |
| Q1 FY2025 | $794.4M+7.9% | $322.2M | $701.9M | $382.8M | $461.2M | $7.74B | N/A | $6.81B |
| Q2 FY2025 | $798.6M+0.5% | $309.5M | $711.0M | $364.5M | $191.7M | $7.91B | N/A | $7.17B |
| Q3 FY2025 | $799.5M+0.1% | $338.7M | $698.6M | $388.5M | $562.1M | $7.35B | N/A | $6.59B |
| Q4 FY2025 | $790.2M-1.2% | $364.3M | $686.8M | $356.7M | $346.2M | $7.88B | N/A | $7.10B |
| Q1 FY2026 | $781.5M-1.1% | $274.9M | $648.1M | $325.8M | $463.3M | $6.71B | N/A | $5.90B |
Balance Sheet Summary (Latest Period)
United Therapeutics Corp (UTHR) Financial Statements & Revenue History
United Therapeutics Corp (UTHR) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $475.45 with a market capitalization of $20. This page provides 41 historical financial statements for United Therapeutics Corp, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, United Therapeutics Corp reported revenue of $3.2 billion, representing 10.6% year-over-year growth. The net profit margin of 41.9% reflects strong profitability..
UTHR Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows United Therapeutics Corp's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether UTHR is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track UTHR's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently United Therapeutics Corp converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of UTHR's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use UTHR Financial Data
Investors use United Therapeutics Corp's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare UTHR's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how UTHR's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View UTHR's financial health score, earnings, and pre-market pricing.
Financial data is sourced from United Therapeutics Corp's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.UTHR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.